Friday, 4 October 2013

Exclusive: Drug firm Ikaria on the block for more than $2 billion - sources

By Greg Roumeliotis and Jessica Toonkel NEW YORK (Reuters) - Ikaria Inc, a private equity and venture capital-backed company whose products are focused on critically ill patients, is exploring a sale that it hopes could value it at more than $2 bi...


more for more more information more info

No comments:

Post a Comment

Note: only a member of this blog may post a comment.